Business
Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors
– Based on continued encouraging efficacy and safety data, metastatic castration-resistant prostate cancer cohort further expanded to 130 patients – –
About this update from Exelixis, Inc.
[{"type":"text","content":"\n – Based on continued encouraging efficacy and safety data,\n metastatic castration-resistant prostate cancer cohort further expanded\n to 130 patients –\n \n \n – Initial data to be presented on February 13 at the 2020 American\n Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU\n 2020) in San Francisco, CA –\n \n\n ALAMEDA, Calif.--(BUSINESS WIRE)--\n Exelixis,\n Inc. (NASDAQ: EXEL) today announced that based on continued\n encouraging efficacy and safety data, the company plans to further\n expand the metastatic castration-resistant prostate cancer (CRPC) cohort\n of COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX®)\n in combination with atezolizumab (TECENTRIQ®) in patients\n with locally advanced or metastatic solid tumors. The cohort, which was\n previously expanded from 30 to 80 patients in July 2019, will now\n include up to 130 patients.\n \n \n “We continue to see encouraging efficacy and safety data from the\n prostate cancer cohort in COSMIC-021,” said Gisela Schwab, M.D.,\n President, Product Development and Medical Affairs and Chief Medical\n Officer, Exelixis. “Expanding this cohort by an additional 50 patients\n will allow us to further document how the combination of cabozantinib\n and atezolizumab may benefit this patient population as we assess our\n potential regulatory plans for the combination and prepare to initiate a\n phase 3 pivotal trial. We look forward to the presentation of initial\n data from this cohort of CRPC patients at ASCO GU 2020 in February.”\n \n \n Based on preliminary encouraging activity, as determined by response\n assessment per Response Evaluation Criteria in Solid Tumors (version\n 1.1) (RECISTv1.1), and safety data of patients enrolled in the\n metastatic CRPC cohort, 50 additional patients with metastatic CRPC (130\n total) who have histologically or cytologically confirmed adenocarcinoma\n of the prostate are being enrolled in the trial.\n \n \n Initial data from the CRPC cohort in COSMIC-021 will be presented at\n ASCO GU 2020 in San Francisco on Thursday, February 13th\n during Poster Session A: Prostate Cancer at 11:30 a.m. – 1:00 p.m. PT\n and again at 5:30 – 6:30 p.m. PT.\n \n \n COSMIC-021 includes 24 cohorts and aims to enroll up to 1,732 patients\n with advanced or metastatic solid tumors including CRPC, renal cell\n carcinoma (RCC), hepa...